Recent genomic studies have identified chromosomal rearrangements defining new subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL), however many cases lack a known initiating genetic alteration. Using integrated genomic analysis of 1,988 childhood and adult cases, we describe a revised taxonomy of B-ALL incorporating 23 subtypes defined by chromosomal rearrangements, sequence mutations or heterogeneous genomic alterations, many of which show marked variation in prevalence according to age. Two subtypes have frequent alterations of the B lymphoid transcription-factor gene PAX5. One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements, intragenic amplifications or mutations); a second subtype is defined by PAX5 p.Pro80Arg and biallelic PAX5 alterations. We show that p.Pro80Arg impairs B lymphoid development and promotes the development of B-ALL with biallelic Pax5 alteration in vivo. These results demonstrate the utility of transcriptome sequencing to classify B-ALL and reinforce the central role of PAX5 as a checkpoint in B lymphoid maturation and leukemogenesis.
B
-progenitor acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy 1 , and it consists of multiple subtypes with distinct constellations of inherited and somatic genetic alterations 2 . Genomic analyses, especially transcriptome sequencing (RNA-seq), have identified recurrent chromosomal rearrangements that lead to expression of chimeric fusion transcripts that define new subtypes of ALL [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In contrast to subtypes characterized by aneuploidy or a single chromosomal rearrangement resulting in expression of chimeric fusion oncoproteins (for example, ETV6-RUNX1, BCR-ABL1 or TCF3-PBX1), rearrangements . There was marked variation in the prevalence of subtypes according to age, with ETV6-RUNX1 and high hyperdiploid ALL being most common in children, and low hypodiploid, KMT2A and kinase-activated (Ph and Ph-like) ALL being more common in adults ( Fig. 1b and Table 1 ).
PAX5-driven
An additional eight subtypes with distinct gene expression profiles and/or common genetic lesions were identified. Some 18 cases (0.9%) harbored rearrangements of BCL2, MYC and/or BCL6, predominantly in adults. These alterations are identical to those observed in double-or triple-hit lymphoma, but have rarely been observed in ALL, and here were of B-cell-precursor immunophenotype 7, 18 . We identified 11 cases (0.6%) with rearrangements of NUTM1 to six different partner genes (three with ACIN1, three with CUX1, two with BRD9 and one for each of IKZF1, SLC12A6 and ZNF618), and nine cases (0.5%) with rearrangement of HLF to TCF3 (n = 8) or TCF4 (n = 1; Fig. 1a , Supplementary Fig. 1 and Supplementary Table 1) . Three groups included cases with similar gene expression profiles to established subtypes but lacking the founding rearrangements: ETV6-RUNX1-like (n = 42), KMT2A-like (n = 5) and ZNF384-like (n = 4). Such cases commonly harbored alternate chromosomal rearrangements-for example, MED12-HOXA9 and AFF1-TMEM156 in KMT2A-like cases, and TCF3-FLI1, FUS-ERG, IKZF1 and alternate ETV6 fusions (two cases with IKZF1-ETV6, two with ETV6-ELMO1 and ten others with different fusion partners; Supplementary Table 1) in ETV6-RUNX1-like cases. In addition, cases with a modal chromosome number [47] [48] [49] [50] and similar gene expression profiles to those in high hyperdiploid ALL were defined as a low hyperdiploid subtype (n = 51), and cases with CRLF2 rearrangement lacking the gene expression profile of Ph-like ALL were assigned as an individual subtype (n = 16), owing to the importance of CRLF2 rearrangement in guiding treatment 5 (Supplementary Table 1 and Supplementary Fig. 1 ).
PAX5 alterations define two subtypes of B-ALL. Two subtypes were characterized by distinct gene expression profiles (defined by hierarchical clustering shown in Supplementary Fig. 1a ) and different types of PAX5 alterations. One, herein termed PAX5-altered (PAX5alt), comprised 148 (7.4%) cases, 109 (73.6%) of which were found with diverse PAX5 alterations, including rearrangements, sequence mutations and focal intragenic amplifications (Fig. 1 , Supplementary Fig. 1 and Supplementary Table 5 ). Children in this subtype were more commonly classified as high risk (n = 63) rather than standard risk (n = 17) according to National Cancer Institute (NCI) criteria. In the PAX5alt group, 57 cases (38.5% of this group) harbored PAX5 rearrangements involving 24 partner genes that led to the expression of chimeric in-frame fusion proteins, the most frequent of which were PAX5-ETV6 (n = 19), PAX5-NOL4L (n = 5), PAX5-AUTS2 (n = 4) and PAX5-CBFA2T3 (n = 4) ( Fig. 2a and Supplementary Table 6 ). Two recurrent PAX5 rearrangements were observed in non-PAX5alt cases. PAX5-JAK2 (n = 17) was exclusively observed in Ph-like ALL, and it encodes an in-frame chimeric fusion protein that leads to constitutive activation of JAK-STAT signaling. Rearrangement of PAX5 with ZCCHC7 immediately 5′ of PAX5 (n = 18, 14 of which were in-frame) was observed in cases with other subtype-defining alterations, including kinase-activating rearrangements (CRLF2, EBF1-PDGFRB and PAX5-JAK2), ETV6-RUNX1 and IGH-DUX4, thus indicating that PAX5-ZCCHC7 is not a leukemia-initiating or subtype-defining event (Supplementary Table 1 and Supplementary Fig. 3a) . Together, the PAX5 rearrangements except PAX5-JAK2 and PAX5-ZCCHC7 were significantly enriched in the PAX5alt group (n = 56, 37.8%) compared with the remaining B-ALL cases (n = 24, 1.3%; two-sided Fisher's exact test, P < 0.0001).
Some 46 (31.1% of this group) PAX5alt cases harbored nonsilent PAX5 sequence mutations, compared with 4.4% (n = 79) of other B-ALL cases, excluding cases defined by PAX5 p.Pro80Arg (described below; two-sided Fisher's exact test, P < 0.0001; Supplementary Fig. 3a ). Among the 62 sequence mutations identified within the PAX5alt group, 27 were homozygous (mutantallele frequency (MAF) range 0.87-1.00, median 0.96), which was commonly due to the loss of the wild-type allele. The remaining 35 heterozygous mutations (MAF range 0.11-0.78, median 0.46) were observed in 19 cases, of which 15 were with two (n = 14) or three (n = 1) mutations ( Fig. 2a and Supplementary Table 7) . Two hotspot missense alterations affecting amino acids Arg38 (n = 20) and Arg140 (n = 11) were identified and were highly enriched in the PAX5alt subtype (n = 11 and 9, respectively). Notably, 10 of 11 Arg140 missense alterations were concomitant with Arg38 alterations, and nine of the cases with these two alterations were classified as PAX5alt, which account for more than half of the PAX5alt cases with multiple alterations (Figs. 2 and 3a) . Among the 203 nonsilent PAX5 mutations identified in this study, 73.9% were missense mutations, especially those involving the DNA-binding domain (94.6%), whereas the more disruptive mutations including frameshift (n = 36), nonsense (n = 4) and splice-site mutations (n = 9) were more commonly observed on the distal region of the PAX5 protein (Fig. 3a) . We also identified a cluster of mutations in the PAX5 nuclear-localization sequence across the spectrum of B-ALL 
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NATURe GeNeTics subtypes; these mutations were predicted to impede translocation of PAX5 to the nucleus (Fig. 3a) . Of the 1,141 cases with SNP array data, 368 (32.2%) had PAX5 CNAs. However, these were not more frequent in the PAX5alt group, except for focal intragenic amplification of PAX5 (PAX5amp), which was identified in ten cases, eight of which were in the PAX5alt group ( Supplementary Fig. 3b) . One of the cases showed that the region of amplification involved exons 2-5 and was predicted to lead to duplication of the PAX5 DNA-binding domain. The structure and consequences of PAX5 amplification were validated by using WGS, PCR with reverse transcription, Sanger sequencing and fluorescence in situ hybridization, showing in-frame internal tandem duplication from exon 2 to exon 5 of PAX5 ( Supplementary Fig. 4 ). Together, genetic alterations of PAX5 were significantly enriched in the PAX5alt group compared with other B-ALL subtypes (73.6% (109 of 148) of PAX5alt versus 5.7% (103 of 1,796) of other samples; two-sided Fisher's exact test, P < 0.0001), except the PAX5 p.Pro80Arg group, as described below (Supplementary Fig. 3c ).
Among the 96 PAX5alt cases with WGS and/or SNP array data, 11.5% (n = 11) lacked an identifiable PAX5 alteration, highlighting the need for complementary data to fully identify the genetic drivers of the PAX5alt gene expression profile in these cases.
In addition to PAX5 alterations, recurrent genetic alterations observed in PAX5alt cases included those affecting cell-cycle regulation (CDKN2A, RB1 and BTG1 deletions), B-cell development (IKZF1, VPREB1 and BTLA deletions), transcriptional regulation (for example, ZFP36L2, ETV6 and LEF1) and/or epigenetic modification (for example, KDM6A, KMT2A and ATRX; Fig. 2b and Supplementary Tables 8 and 9 ). Notably, signaling-pathway mutations were observed in 63.1% (41 out of 65 cases with WES or WGS data) cases in this subtype. The gene expression profile of PAX5alt was notable for a preponderance of downregulated genes, as compared with other B-ALL cases (319 upregulated and 2,150 downregulated genes with changes twofold or greater and adjusted P < 0.01) ( Supplementary Tables 10 and 11 ), thus suggesting that loss of PAX5 transcriptional activation promotes leukemogenesis. Pathway Supplementary Fig. 1a ). In 30 cases, the mutation encoding PAX5 p.Pro80Arg was hemizygous or homozygous, owing to deletion of the wild-type PAX5 allele or copy-neutral loss of heterozygosity (Fig. 3b,c 
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NATURe GeNeTics and 14) . Of the remaining 14 cases with heterozygous PAX5 p.Pro80Arg-encoding alterations, 13 harbored a second frameshift (n = 7), nonsense (n = 2) or deleterious missense (n = 4) PAX5 mutation. Although four of the remaining 1,944 cases also harbored the PAX5 p.Pro80Arg alteration, all were heterozygous with preservation of a wild-type PAX5 allele and had similar gene expression profiles to those of other subtypes (two Ph-like, one BCL2/MYC and one PAX5alt), in agreement with the notion that biallelic PAX5 alterations, including those encoding p.Pro80Arg, are a hallmark of this subtype.
Collectively, signaling-pathway alterations (in the Ras and JAK/ STAT pathways, FLT3, BRAF and PIK3CA) were present in 42 (95.5%) of PAX5 p.Pro80Arg cases, thereby suggesting cooperativity between deregulated PAX5 activity and kinase signaling in leukemogenesis. The Ras pathway was particularly frequently mutated, most commonly with NRAS, KRAS, PTPN11 and NF1 alterations (n = 33, 75.0% vs 27.7% (538 of 1,944) in other B-ALL, two-sided Fisher's exact test, P < 0.0001; Fig. 3c and Supplementary Tables  15-16 ). Most Ras nonmutated PAX5 p.Pro80Arg cases harbored alterations in JAK/STAT pathway members, most commonly the interleukin 7 (IL-7) receptor (IL7R, n = 7). We compared the distribution of mutations in each signaling pathway (Ras and JAK-STAT pathway members and FLT3) across B-ALL subtype and observed significant enrichment, particularly in Ras and JAK-STAT pathway SJBALL042304  SJBALL048066  SJHYPO112  SJALL049956  SJALL054506  PATAAH  SJBALL021043  SJBALL021082  SJHYPO102  SJALL040076  SJBALL020739  SJBALL015144  SJBALL047022  SJBALL015077  SJBALL020807  SJALL014946  SJALL049973  SJBALL020666  SJBALL015072  SJALL049939  SJBALL015056  SJBALL046123  SJBALL014011  SJBALL015  SJBALL192  SJHYPO103  SJALL050013  SJBALL020651  SJBALL043656  SJBALL014464  SJBALL015137  SJBALL021772  SJBALL016250  SJBALL021104  SJBALL015118  SJALL054485  SJBALL013378  SJBALL042286  SJBALL014044  SJBALL020789  SJBALL020098 Table 7 . Individual cases are represented by circles; missense mutations affecting the same amino acid residues are shown as graded shades of blue to indicate the number of cases for each substitution. b, CNAs identified on chromosome 9 from SNP arrays. Two commonly altered genes (CDKN2A and PAX5) affected by CNAs are highlighted. Hemi, hemizygous; homo, homozygous. c, Genetic mutations including SNVs, indels and CNAs detected from transcriptome sequencing, WGS, WES or SNP array data in the PAX5 P80R group. Genes are ordered according their recurrence and grouped into specific pathways. Zygosity of the PAX5 P80R alteration (PAX5 P80R) is shown between copy number of PAX5 (PAX5 CNA) and detailed PAX5 mutations (PAX5 (44) , indicating 44 cases with PAX5 mutations) to illustrate that homozygous PAX5 mutations result from a loss of the wild-type allele of PAX5, whereas cases with heterozygous P80R mutations are usually observed with a second hit to disrupt function of the other copy of PAX5.
NATURe GeNeTics members, in the PAX5 p.Pro80Arg group (90.1% of 44 PAX5 p.Pro80Arg versus 35.3% of 1,944 other B-ALL, two-sided Fisher's exact test, P < 0.0001; Fig. 4a) . NRAS, PTPN11 and IL7R were most frequently mutated in the PAX5 p.Pro80Arg group compared with other B-ALL subtypes (47.7, 29.5 and 27.3%, respectively; Fig. 4b ). We examined coding-sequence mutations genome wide and found an additional target of mutation that was most commonly mutated in PAX5 p.Pro80Arg cases, SETD2, which encodes a histone 3 Lys36 trimethylase (25.0% versus 6% of other B-ALL cases) 19, 20 . The gene expression profile of PAX5 p.Pro80Arg ALL (334 upregulated and 2,552 downregulated genes with twofold change or greater and adjusted P < 0.01; Fig. 5a and Supplementary Table 17) showed limited overlap of upregulated genes with the signature of PAX5alt ALL (9.9%, n = 33 genes). However, approximately half (n = 1,224) of the downregulated genes in these two groups were shared, indicating loss of PAX5 transcriptional activity in both the PAX5 p.Pro80Arg and PAX5alt groups (Fig. 5b) . In agreement with the higher frequency of mutations in signaling pathways compared with that in the PAX5alt group, there was greater expression of genes encoding regulators of cytokine-receptor signaling (Supplementary  Tables 18-19) . Moreover, direct comparison of p.Pro80Arg versus PAX5alt ALL showed negative enrichment of B-lineage genes in p.Pro80Arg ALL, including targets of PAX5 such as BACH2 (ref. 21 ), thus indicating that p.Pro80Arg has more profoundly deleterious effects on B cell maturation than the alterations collectively present in PAX5alt ALL (Fig. 5c and Supplementary Table 20) . Notably, the MEGF10 gene (encoding multiple epidermal growth factor-like domains protein 10), which was otherwise silent or poorly expressed in normal B cells and other B-ALL subtypes, was markedly overexpressed in PAX5 p.Pro80Arg cases (log 2 fold change 7.74, adjusted P = 6.13 × 10 -111 ), suggesting that increased expression of this gene may serve as a biomarker and/or driver of this subtype. IKZF1 p.Asn159Tyr alteration defines a B-ALL subtype. The data described above suggest that sequence mutations may serve as initiating, subtype-defining events in B-ALL rather than being secondary, cooperating events in leukemogenesis. In agreement with this idea, we observed an additional subtype that was defined by a single transcription-factor alteration. Eight cases harbored heterozygous IKZF1 p.Asn159Tyr-encoding missense alterations, and in contrast to PAX5 p.Pro80Arg ALL, retention of expression of the nonmutated IKZF1 allele. The gene expression profile was markedly distinct from those of other B-ALL cases, including other IKZF1-altered cases (593 upregulated and 1,227 downregulated genes with twofold change or greater and adjusted P < 0.01; Fig. 1a , Supplementary Fig. 1a and Supplementary Table 23 ). Subjects with PAX5 p.Pro80Arg and PAX5alt subtypes had median presenting white-blood-cell counts of 13.0 × 10 9 l -1 and 16.9 × 10 9 l -1
, respectively, and were more likely to be male (65.9% and 68.9%) (Supplementary Table 23 ). Positive minimal residual disease (≥ 0.01%) at the end of induction was detected in 7.2% and 29.4% of PAX5 p.Pro80Arg and PAX5alt cases, respectively (Supplementary Table 24 ). In children treated in the Children's Oncology Group AALL0232 study of NCI high-risk B-ALL 26 , the outcome was intermediate for both PAX5 p.Pro80Arg (5-year event-free survival (EFS) 75.0 ± 14.2%, overall survival (OS) 75.0 ± 14.2%, eight evaluable cases) and PAX5alt (EFS 71.5 ± 7.0%, OS 75.7 ± 6.6%, 46 evaluable cases) compared with DUX4 ALL and other favorable risk subtypes (high hyperdiploid, ETV6-RUNX1 and TCF3-PBX1; Fig. 6a, Supplementary Table 25 ). In contrast, the outcome for PAX5 p.Pro80Arg in children treated on St. Jude Total Therapy protocols was unfavorable, although few subjects were evaluable and were treated on multiple protocols (Supplementary Table 25 ). Adults with PAX5 p.Pro80Arg ALL (15 of 288 evaluable cases) had intermediate and superior outcomes (EFS 63.0 ± 13.3%, OS 61.9 ± 13.4%) compared with those of subjects with PAX5alt (EFS 32.2 ± 9.4%, OS 42.1 ± 10.2%, 27 evaluable cases). Notably, in adults, the DUX4 subtype was associated with excellent outcome, and BCL2/MYC was associated with uniformly early treatment failure (Fig. 6b and Supplementary Table 26 ). Fig. 7b-d) . Secondary transplantation into sublethally irradiated recipients led to rapid development of leukemia (Fig. 7e) . In contrast, the PAX5 p.Gly183Ser octapeptide-domain alteration did not induce leukemia. Array comparative genomic hybridization analysis of the mouse tumors identified CNAs of Pax5 in two of three leukemias that arose in Pax5 p.Pro80Arg/+ mice ( Fig. 7f and Supplementary Table 29 ). These included a deletion of the entire Pax5 locus leading to monoallelic expression of Pax5 p.Pro80Arg, and a truncating frameshift mutation of the wild-type allele (Fig. 7g) , recapitulating loss of the wild-type PAX5 allele observed in human PAX5 p.Pro80Arg ALL. Although no CNA was observed of Pax5 in one leukemia, the MAF of p.Pro80Arg was 0.98, as determined by RNA-seq analysis, thus suggesting duplication of the mutant allele to homozygosity by copy-neutral loss of heterozygosity. Amplification of the entire Pax5 locus was observed in a Pax5 p.Pro80Arg/p.Pro80Arg tumor, accompanied by high expression of . Antibodies to PAX5 detecting N or C terminus (N-term. or C-term.) were used to confirm a truncation observed in 731-1. Actin was used as a loading control. Immunoblots were repeated three times. h, GSEA for PAX5 P80R human B-ALL subtype versus normal human B cells isolated from the bone marrow. Gene sets were derived from the top 500 upregulated or downregulated genes between Pax5 P80R (n = 4) leukemia cells vs normal B samples (n = 3) from mouse model. FDR, nominal P value and normalized enrichment score were calculated by GSEA 35 . mutant Pax5 p.Pro80Arg (Fig. 7f) . Primary tumors harbored multiple Jak1 and/or Jak3 mutations (Supplementary Tables 30-32) , most of which lead to constitutive activation of JAK/STAT signaling 29 . Cells grown in vitro from secondary transplants showed hyperphosphorylation of STAT5 (Fig. 7g) that was inhibited by ruxolitinib, thus resulting in half-maximal lethal concentration values in cytotoxic assays ranging from 10 to 50 nM (data not shown). Gene set enrichment analysis (GSEA) showed significant similarity of gene expression profiles of mouse and human PAX5 p.Pro80Arg leukemias (Supplementary Table 33 and Fig. 7h ). These data support the notion that PAX5 p.Pro80Arg is an initiating lesion and cooperates with activated kinase signaling in leukemogenesis.
Discussion
This study identifies multiple new subtypes of B-ALL that exhibit distinct genomic, clinical and outcome-based features, and variation in prevalence according to age. Although recent studies have identified several new targets of rearrangement in B-ALL (for example, DUX4, ZNF384 and MEF2D), here we show the power of transcriptome sequencing of large cohorts of ALL to identify new subtypes of heterogeneous genetic basis according to gene expression profile clustering, the marked variance in subtype prevalence by age and the observation that transcription-factor missense mutations are initiating, subtype-defining leukemogenic alterations. Moreover, integrative multimodal genomic analysis has distilled the often diverse alterations that define subgroups that had previously defied classification, particularly PAX5alt ALL, with its characteristic PAX5 rearrangements, sequence mutations and focal amplifications. Identification and description of these subtypes account for many of the cases termed B-other, which lacked a subtype-defining lesion and previously eluded accurate risk stratification. Specifically, the PAX5alt and PAX5 p.Pro80Arg subtypes account for 9.7% of those cases previously termed B-other. Moreover, subtypes associated with unfavorable outcomes, such as KMT2A-rearranged, low hypodiploid and kinase-driven ALL account for > 65% of adult cases, indicating that the genomic subtype is a central determinant of the poor outcome characteristic of ALL in older individuals.
Our results also highlight the importance of PAX5 in regulating B cell lineage differentiation and of PAX5 alterations as central events in B lymphoid leukemogenesis. PAX5 encodes a paired box DNA-binding transcription factor that regulates B lymphoid lineage commitment and maturation 30, 31 . Prior studies have identified frequent PAX5 alterations in ALL, including rearrangements, focal deletions, sequence mutations and intragenic amplification 27, 32 . With the exception of PAX5 rearrangements and the germline PAX5 p.Gly183Ser-encoding alteration 28 , these alterations have been considered secondary events that contribute to the arrest in lymphoid maturation characteristic of the disease. The current study indicates that PAX5 alterations may be initiating, subtype-defining events in B-ALL. The PAX5 Pro80 residue is located at a region of the paired domain that directly contacts the minor groove of DNA, impairs binding of PAX5 to targets and partly attenuates transcriptional activation 27 . In more physiologic assays such as activation of CD79A (a PAX5-regulated gene that encodes the Ig-α protein of the B-cell antigen receptor) and expression of surface immunoglobulin, and as shown in this study, B-cell differentiation, PAX5 p.Pro80Arg is profoundly deleterious and leads to arrest in maturation at the pro-to pre-B-cell stage. This subtype of B-ALL is also notable for the near-universal inactivation of the wild-type PAX5 allele, by deletion, acquired copy-neutral loss of heterozygosity that duplicates the mutant allele or acquisition of a second PAX5 sequence mutation that leads to loss of function. The importance of biallelic alterations of PAX5 in this subgroup is supported by the knock-in Pax5 p.Pro80Arg mouse model of ALL, in which most tumors acquire second hit alterations of Pax5, either by deletion of the wild-type allele or by amplification of mutant Pax5.
The utility of transcriptomic gene expression profiling to classify B-ALL and identify new subtypes is further supported by the identification of the more genetically diverse PAX5-altered group. Although multiple prior studies have identified PAX5 rearrangements that lead to a chimeric fusion that retains the paired domain of PAX5 at the N terminus with variable loss of the distal, transcriptional regulatory domains 27, 33 , a B-ALL subtype enriched for PAX5 alterations had not previously been recognized, in part owing to the genetic heterogeneity of this PAX5alt group. Additional genetic alterations, particularly intragenic PAX5 amplification and nonp.Pro80Arg sequence alterations, are also significantly enriched in this group. Such alterations are identified at much lower frequency in other subtypes, except rearrangements of PAX5 to JAK2 and ZCCHC7 in Ph-like ALL 5 . In this context, the gene expression profile is consistent with that of Ph-like ALL rather than the PAX5alt group. Thus, accurate subgroup assignment requires consideration of transcriptional gene expression profiles in addition to identification of PAX5 alterations.
These results have important clinical implications for diagnosis and risk stratification. We show diversity in treatment outcomes according to subtype, with PAX5 p.Pro80Arg and PAX5alt cases having intermediate to poor outcome in children and adults with B-ALL. This is consistent with prior observations that forms of leukemia with more stem-cell-like features, such as KMT2A-rearranged and IKZF1-mutated Ph + or Ph-like ALL, have inferior outcomes. Our findings suggest that new therapeutic approaches should be explored, including targeting of the deregulated signaling pathways in PAX5 p.Pro80Arg ALL. These results are also of immediate diagnostic importance, because they suggest that most B-ALL cases, and their underlying driver alterations, may be rapidly detected by analysis of transcriptome sequencing to guide classification, risk stratification and tailored therapy.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0315-5. ; (ClinicalTrials.gov identifier NCT00137111) and Total XVI protocols (NCT00549848); the COG P9906 highrisk B-ALL study 38 ; the COG AALL0232 high-risk ALL study 26 (NCT00075725); the COG AALL0331 standard-risk ALL study (NCT00103285); the ECOG-ACRIN E2993 (ref. 39 ); (NCT00002514) and E1910 trials (NCT02003222); the MD Anderson Cancer Center protocols [40] [41] [42] [43] ; the Alliance-Cancer and Leukemia Group B protocols C19802 (NCT00003700), C10102 (NCT00061945) and C10403 (NCT00558519); and SWOG protocols S0333 (NCT00109837) and S9400 (NCT00002665). Detailed clinical information for each case is provided in Supplementary Table 1 . The subjects enrolled in this study have provided written informed consent, assent (as appropriate), or parental consent (as appropriate) as part of their protocols for research including genetic research. All relevant ethical regulations were strictly followed during this study.
Transcriptome sequencing. RNA-seq was performed using TruSeq library preparation and HiSeq 2000 and 2500 sequencers (Illumina). All sequence reads were paired-end, and were performed by using (i) total RNA and stranded RNAseq (75-or 100-base pair (bp) reads); (ii) poly(A)-selected mRNA (50-, 75-or 100-bp reads). Sequencing reads were mapped to the GRCh37 human genome reference by STAR 44 (version 2.4.2a), through the suggested two-pass mapping pipeline. Gene annotation downloaded from the Ensembl website (see URLs) was used for STAR mapping and the following read-count evaluation. All the samples were sequenced with RefSeq coding region covered with 30-fold coverage ≥ 15% (median ± s.d., 37.2 ± 7.5%). CICERO 5 and FusionCatcher 45, 46 were used to detect fusions, and all the reported rearrangements were manually reviewed to keep the reliable ones. Owing to the complexity of DUX4 rearrangements, some of the DUX4 fusions were manually rescued by checking the aligned reads within IGV browser 47 . RNA extracted from flow-sorted normal B lymphoid cells were used for RNA-seq and details are in our previous study 48 .
Gene expression level evaluation from RNA-seq data. To evaluate gene expression level, the read count for each annotated gene was calculated with the HTSeq package 49 , and gene expression level normalization and differential expression analysis were carried out with the DESeq2 Bioconductor R package 50 .
To evaluate the digital gene expression level, a regularized log-transformed (rlog) value was calculated by DESeq2. The ComBat function in the sva R package 51 was used to correct the batch effect introduced by different library preparation strategies and sequencing lengths. With the rlog gene expression level, the R package Rtsne was used to map the samples to a two-dimensional tSNE plot with the top 1,000 most variable genes (on the basis of median absolute deviation), and the tSNE perplexity parameter was set to 30. Different gene numbers (200, 500, 1,000 and 2,000) and tSNE parameters (perplexity of 20, 30, 40 and 50) were explored, and stable clusters were observed. Gene signature analysis was also carried out by DESeq2 with default parameters to evaluate the differentially expressed genes.
Copy number alteration detection from RNA-seq data. RNA-seq data are not optimal for calling genomic-level CNAs but are still informative for evaluating chromosome or arm-level copy number changes for cases lacking karyotypic or DNA array data. To accomplish the latter, we ordered the genes on the basis of the median absolute deviation of their expression level across the samples, and then picked a subset (one-fourth to one-third) of the genes with least median absolute deviation as stably expressed genes. To assist in the CNA calling, the MAF of single-nucelotide variants (SNVs) detected from RNA-seq data was also plotted against the gene expression levels of the stably expressed genes to double-check whether the CNAs were reliable (Supplementary Fig. 7 ). This strategy was mainly applied to resolve the B-ALL subtyping issue for potential hyperdiploid and hypodiploid cases without karyotypic information. An evaluation was performed in 30 aneuploid cases (7 high hyperdiploid, 21 low hypodiploid and 2 near haploid) with chromosomal-level CNAs called from both SNP array and RNA-seq data (Supplementary Table 34 ). In total, 295 CNAs were called from the SNP array data, and 285 (96.6%) could be faithfully recapitulated by RNA-seq data, indicating that the application of RNA-seq to evaluate chromosomal level CNAs was highly reliable. One false-positive CNA called from RNA-seq was on the X chromosome, and ten false-negative CNAs missed by RNA-seq were mainly on sex chromosome X (n = 8) and may be explained by X chromosome inactivation.
Mutation detection from RNA-seq data. The SNVs and indels were called from RNA-seq data by following the best practice workflow from the GATK 52 forum (see URLs). In general, STAR-mapped bam files were processed by Picard (see URLs, version 1.129) to mark duplicate reads, and then GATK module SplitNCigarReads was used to split reads into exon segments and hard-clip any sequences overhanging into the intronic regions. Mutations were called by the HaplotypeCaller module in GATK, and the following criteria were applied to retain the high-quality mutations: (i) at least three reads supported the mutation, and the MAF was ≥ 0.05; (ii) the mutation was not observed in the common SNP database dbSNP 150; (iii) the mutation was not observed in two or more samples from our germline exome sequence cohort (775 samples). After filtering, all the mutations were annotated to RefSeq genes, and nonsilent mutations that have been previously validated according to the COSMIC database V84 (see URLs) and/or PeCan portal (see URLs) were kept for further analysis.
Whole-genome and whole-exome sequencing. WGS of leukemia and paired germline samples was carried out by TARGET (Therapeutically Applicable Research To Generate Effective Treatments program; see URLs) and SJCRH. WES was performed at SJCRH.
For WGS data generated by TARGET, methods for DNA preparation, sequencing and quality control are available at the TARGET Project portal (see URLs). For WGS performed at SJCRH, genomic DNA was quantified by using the Quant-iT PicoGreen assay (Life Technologies). Genomic DNA was sheared on an LE220 ultrasonicator (Covaris). Libraries were prepared from sheared DNA with HyperPrep Library Preparation Kits (Kapa Biosystems). Libraries were analyzed for insert size distribution with a 2100 BioAnalyzer High Sensitivity kit (Agilent Technologies) or Caliper LabChip GX DNA High Sensitivity Reagent kit (PerkinElmer). Libraries were quantified by using the Quant-iT PicoGreen dsDNA assay (Life Technologies). Paired-end 150-cycle sequencing was performed on a NovaSeq 6000 (Illumina). For WES at SJCRH, library preparation was performed with Nextera rapid exome kit (Illumina), by using the Caliper Biosciences (Perkin Elmer) Sciclone G3. First-round PCR (ten cycles) was performed with Nextera kit reagents (Illumina), and cleanup steps used BC/Agencourt AMPure XP beads. Target capture was done with a Nextera rapid capture exome kit (Illumina) and the supplied hybridization and associated reagents. Library quality control was performed with a Victor fluorescence plate reader with Quant-it dsDNA reagents for prepool quantification, and a Bio-analyzer 2200 (Agilent) was used for final library quantification. Paired-end sequencing was performed with a HiSeq 2000 or 2500 (Illumina) instrument with a read length of 100 bp.
WGS and WES read alignment and quality control. Paired-end WGS and WES reads were mapped to human reference genome GRCh37 by BWA 53 (version 0.7.12). Samtools 54 (version 1.3.1) was used to generate chromosomal coordinatesorted and indexed bam files, which were then processed by the Picard (see URLs, version 1.129) MarkDuplicates module to mark PCR duplications. Then the reads were realigned around potential indel regions by the GATK 55 (version 3.7) IndelRealigner module. Sequencing depth and coverage was assessed based on coding regions (~34 Mb) defined by RefSeq genes.
WGS and WES mutation calling and filtering workflow. UnifiedGenotyper (within GATK v3.7) and muTect2 (beta version within GATK v4) modules were applied to call SNVs and indels from leukemia and paired germline samples. The raw mutations were filtered by a homemade pipeline to exclude (i) reported common SNPs or indels from dbSNP v150 and (ii) germline mutations detected from matched germline control samples. All the nonsilent SNVs or indels that passed the filtering pipeline were manually reviewed, and only the highly reliable somatic ones were reported. Meanwhile, adjacent nucleotide changes observed on the same allele were merged into one mutation.
CNA and loss of heterozygosity detection from microarrays. SNP microarray data from two different platforms were used in this study: Illumina Infinium Omni2.5 Exome-8 (2.6 million probes) and Affymetrix Genome-Wide Human SNP Array 6.0 (1.8 million probes). For the Illumina platform, DNA extracted from leukemia and matched germline samples was hybridized to the SNP array according to the manufacturer's protocol. The raw intensity data (*.idat files) were analyzed by the Genotyping Module from Illumina GenomeStudio software (version 2.0.3). Normalized log R ratio and B allele frequency for all the available probes were evaluated. All the Affymetrix SNP data are from our previous study and have been thoroughly analyzed 5, 56 . Affymetrix SNP data for the PAX5 p.Pro80Arg samples were converted to log R ratio and B allele frequency values by following the pipeline suggested by PennCNV 57 (see URLs). With the input of log R ratios and B allele frequencies, somatic CNA and loss of heterozygosity from paired or unpaired samples were called by OncoSNP 58 (version 2.1) and manually reviewed by ShinyCNV 59 . Only the somatic alterations meeting the criteria proposed by OncoSNP and PennCNV were kept for further analysis.
Gene-set enrichment and pathway analysis. Raw read counts from RNA-seq data were imported to DESeq2 for differential gene expression analysis. To perform GSEA 35 , we defined the gene expression profile of PAX5 p.Pro80Arg by comparing gene expression levels between PAX5 p.Pro80Arg ALL and normal B cells purified from human bone marrow, and ranking genes according to fold change and significance. GSEA was performed by using mSigDB C2 genes and curated gene sets from in-house analyses. Significantly regulated genes (twofold change or greater and adjusted P < 0.01) were selected for Kyoto Encyclopedia of Genes and Genomes pathway and gene-ontology enrichment analysis by GO-Elite 60 .
Animals. Mice were housed in an American Association of Laboratory Animal Care-accredited facility, and all experiments were approved and were in compliance with the SJCRH Institutional Animal Care and Use Committeeapproved protocol in accordance with National Institutes of Health guidelines.
Pax5
-/-mutant mice 31 were provided by M. Busslinger and maintained on the C56BL/6 background. Genotyping was determined by PCR analysis as described 61 . Supplementary Table 27 . sgRNAs were designed and generated as described 62 . Cas9 mRNA transcripts were also generated as described 62 . The target site for each sgRNA is unique in the mouse genome, and no potential off-target site with fewer than three mismatches was found by using the Cas-OFFinder algorithm 63 (Supplementary Table 28 ).

p.Pro80Arg and Pax5 p.Gly183Ser loci were genotyped by PCR using primers Pax5-e3-F1 and Pax5-e3-R1, or Pax5e5-F1 and Pax5e5-R1, and subsequent Sanger sequencing of the PCR amplicon (Supplementary Table 27 ).
For leukemia studies, heterozygous mice for each allele were interbred, and the offspring were monitored daily for signs of illness. Moribund mice were killed, and complete blood counts were taken from peripheral blood. Bone marrow and spleen samples were collected and analyzed by flow cytometry for lineage markers (Mac1-Alexa700, Gr1-PerCP-Cy5.5, B220-eFluor605, CD3-APC, CD41-PE and Ter119-V500) and Hardy panel B-lymphocyte markers (CD43-PerCP-Cy5.5, B220-eFluor605, CD19-APC-Cy7, BP1-APC and IgM-PE-Cy7) to determine the immunophenotype of leukemic cells. For western blotting, cells were lysed in RIPA buffer, subjected to SDS-polyacrylamide gel electrophoresis, and probed with antibody to PAX5 (Millipore; 05-1573, clone 1H9).
Retroviral vectors and retrovirus production.
Vector production was performed as described by Mullighan et al 27 . Briefly, the coding regions of the exon 1a isoforms of wild-type and mutant PAX5 were cloned from B-ALL subjects into the XhoI site of the retroviral MSCV-IRES-mRFP (MIR) vector. The Eco Phoenix packaging system was used to produce ecotropic retrovirus. Briefly, 24 h after Eco Phoenix cells were plated in complete DMEM medium, the cells were transfected with wild-type PAX5, mutant PAX5 or MIR plasmid DNA by using FuGENE 6 according to the manufacturer's instructions (Roche Diagnostics). 24 h later, the medium was removed and replaced with complete IMDM. Viral supernatant was collected starting at 48 h after transfection, filtered through a 0.45-μ m filter (Millipore) , divided into aliquots and frozen at − 80 °C until use. Virus titration was performed by transduction of NIH3T3 fibroblast cells and quantification of red fluorescent protein (RFP) expression at 48 h. Viral titers ranged from 10 5 to 10 6 virus particles per milliliter, depending on the construct, and these titers were highly reproducible. Flt3L, 30 ng ml -1 IL-6, 20 ng ml -1 IL-3 and 20 ng ml -1 IL-7 from PeproTech. Up to 2 million Lin -cells were transduced in Retronectin (Takara)-coated plates preloaded with viral supernatants and cultured in the presence of cytokines for 2 d. RFP + cells were isolated by flow-activated sorting and cultured for 13 d on an IL-7-producing irradiated T220 stromal cell line. Cells were then harvested for immunophenotyping using allophycocyanin (APC)-, APC-Cy7-, fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, peridinin-chlorophyll-protein (PerCP) cy5.5-, PE-cy7-or biotin-conjugated monoclonal antibody to B220, CD19, BP-1, IgM, CD5 (Ly-1), Ly-6G (Gr-1), CD45R/B220 or TER119 (BD Biosciences). Staining of cells was performed by using standard protocols, and analysis was done in the presence of 4,6-diamidino-2-phenylindole (DAPI) nucleic acid to exclude dead cells. Cell sorting was done on a FACSVantage or FACSDiva Cell Sorter (BD Biosciences). Data were analyzed by using FlowJo software (Treestar) and are expressed as the percentage of positive cells for the specific B-ell antigens. Each experiment was repeated at least three times.
Retroviral transduction and ex vivo culture of
Statistical analysis.
Associations among categorical values were examined using two-sided Fisher's exact test. Associations among B-ALL subtypes and EFS and OS were examined by the Kaplan-Meier estimator, with Peto's estimator of standard deviation and the two-sided time-stratified Cochran-Mantel-Haenszel test 64 . An event was defined as a failure to achieve remission, a relapse after remission, or the development of a second malignant neoplasm. A multivariate analysis of event-free and overall survival was performed with the Cox proportional hazards regression model 65 . Analyses were performed by using Prism version 7.0 (GraphPad Software), R version 3.4.3 (see URLs) and SAS software version 9.4 (SAS Institute).
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The raw and analyzed data are provided in a graphical, interactive platform (see URLs). Genomic data generated for this study have been deposited in the European Genome-phenome Archive (EGA) under accession number EGAS00001003266. Other legacy data used in this study have been deposited in the EGA in previous projects under accession numbers EGAS00001000654, EGAS00001001952, EGAS00001001923, EGAS00001002217 and EGAS00001000447. The TARGET genomic data used in this study are available through the TARGET website (see URLs) and also in dbGaP (see URLs) under accession number phs000218 (TARGET). The other data supporting this study are available from the corresponding author upon reasonable request. ) Cell population abundance 100% of the post-sort fraction were the relevant RFP+ cells.
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cryocontainers filled with isopropanol . For flow analysis, cells were thawed and stained for surface markers. Normal bone marrow was used for isotype and antibody controls for comparison to tumor samples. Instrument Flow cytometric analysis and sorting was performed with FACSVantage or FACSDiva Cell Sorter (BD Biosciences) Software Data was analyzed using FlowJo10 software (Treestar Inc.
Gating strategy
Live cells were gated by Dapi vs FSC which were further gated to singlets by FSC vs SSC. Isotype controls and untransduced cells were used for setting gates for negative populations.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. nature research | flow cytometry reporting summary November 2017
